- Home
- INVE vs OVID Comparison
INVE vs OVID Comparison
Compare INVE & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- OVID
- Stock Information
- Founded
- INVE 1990
- OVID 2014
- Country
- INVE United States
- OVID United States
- Employees
- INVE N/A
- OVID N/A
- Industry
- INVE Computer peripheral equipment
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- OVID Health Care
- Exchange
- INVE Nasdaq
- OVID Nasdaq
- Market Cap
- INVE 85.9M
- OVID 88.9M
- IPO Year
- INVE 1997
- OVID 2017
- Fundamental
- Price
- INVE $3.78
- OVID $1.74
- Analyst Decision
- INVE Strong Buy
- OVID Strong Buy
- Analyst Count
- INVE 2
- OVID 4
- Target Price
- INVE $5.50
- OVID $3.13
- AVG Volume (30 Days)
- INVE 27.5K
- OVID 5.1M
- Earning Date
- INVE 11-06-2025
- OVID 11-11-2025
- Dividend Yield
- INVE N/A
- OVID N/A
- EPS Growth
- INVE N/A
- OVID N/A
- EPS
- INVE 3.12
- OVID N/A
- Revenue
- INVE $23,538,000.00
- OVID $6,651,000.00
- Revenue This Year
- INVE N/A
- OVID $1,086.57
- Revenue Next Year
- INVE $9.06
- OVID N/A
- P/E Ratio
- INVE $1.19
- OVID N/A
- Revenue Growth
- INVE N/A
- OVID 1070.95
- 52 Week Low
- INVE $2.86
- OVID $0.24
- 52 Week High
- INVE $4.29
- OVID $2.01
- Technical
- Relative Strength Index (RSI)
- INVE 56.76
- OVID 61.83
- Support Level
- INVE $3.33
- OVID $1.57
- Resistance Level
- INVE $3.80
- OVID $2.01
- Average True Range (ATR)
- INVE 0.15
- OVID 0.21
- MACD
- INVE 0.02
- OVID 0.01
- Stochastic Oscillator
- INVE 91.53
- OVID 65.24
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.